secwatch.observer — SEC 8-K summary
======================================

Issuer:     CNS Pharmaceuticals, Inc. (CNSP)
CIK:        0001729427
Form:       8-K
Filed at:   2026-02-17T23:59:59+00:00
Accession:  0001683168-26-001066
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CNS Pharmaceuticals appoints Steve O'Loughlin as CFO; current CFO Downs moves to SVP Finance
--------------------------------------------------------------------------------

- Steve O'Loughlin appointed CFO effective March 2, 2026; base salary $450,000, target bonus 40% of base.
- O'Loughlin receives initial RSU grant of 9,500 shares; 25% vest at 6 months, 25% at 12 months, 50% quarterly thereafter.
- Current CFO Christopher Downs resigns as CFO, becomes SVP - Finance effective March 2; base salary $350,000, target bonus 30%.
- Both employment agreements include 6-month severance (base salary) for termination without cause or for good reason.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1729427/000168316826001066/0001683168-26-001066-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1729427/000168316826001066/cns_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-26-001066

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer